Lyophilized Injectable Market to Grow with a CAGR of 9.28% through 2028
Increase in the Demand for Biologics and Specialty
Drugs and Extended Shelf Life and Improved Stability is expected to drive the
Global Lyophilized Injectable Market growth in the forecast period, 2024-2028.
According to
TechSci Research report, “Lyophilized Injectable Market – Global Industry
Size, Share, Trends, Competition Forecast & Opportunities, 2028”,
the Global Lyophilized Injectable Market stood at USD 2.81 billion in 2022 and
is anticipated to grow with a CAGR of 9.28% in the forecast period, 2024-2028.
The awareness among individuals regarding Lyophilized Injectable has led to
favorable market conditions for the global Lyophilized Injectable market.
Several factors contribute to the growth of various Lyophilized Injectable
products.
The growing
prevalence of chronic diseases, such as diabetes and cancer, has led to an
increased need for biologic drugs. This demand, coupled with advancements in
biotechnology, has driven pharmaceutical companies to develop and manufacture a
wider range of lyophilized injectable formulations. The
rising demand for biologics and specialty drugs. These drugs, often used for
complex medical conditions like cancer, autoimmune diseases, and rare
disorders, require a stable and long-lasting form of administration.
Lyophilized injectables offer a solution by providing a stable platform for the
storage and delivery of these sensitive drugs.
Browse over XX
market data Figures spread through XX Pages and an in-depth TOC on "Lyophilized Injectable Market”
The development
of innovative drug delivery technologies has been a significant driver for the
Lyophilized Injectable Market. These technologies enable precise dosing,
improved patient compliance, and more convenient administration routes,
fostering the growth of injectable formulations. The
emergence of pre-filled syringes and auto-injectors has made it easier for
patients to self-administer lyophilized injectable medications, which will
further fuel market growth.
B. Braun and
Siemens Healthineers are collaborating to develop new digital solutions for
healthcare. This collaboration will combine B. Braun's expertise in medical
devices and Siemens Healthineers' expertise in digital technologies to create
innovative new solutions that improve the quality and efficiency of healthcare.
Lyophilized
Injectable serve as hormones, coenzymes, and antioxidants, all of which are
vital for proper bodily functions. Factors such as evolving dietary
preferences, busy lifestyles, increased employment levels, and growing
awareness of the health benefits of Lyophilized Injectable are expected to
positively impact the global Lyophilized Injectable market.
In today's
fast-paced world, Lyophilized injectables are designed for quick and easy
reconstitution. In a busy healthcare setting, healthcare providers can rapidly
prepare and administer these drugs, saving valuable time when every second
counts. Lyophilization significantly extends the shelf life of injectable
medications. This means that healthcare facilities can stock lyophilized drugs
for longer periods without the risk of expiration, reducing the need for
frequent restocking and inventory management. Lyophilized formulations are
stable and less prone to degradation, ensuring that the medication remains
effective over time. This stability is crucial in the fast-paced world where
patients need reliable treatments for various medical conditions. In emergency
medical situations, lyophilized injectables provide a ready-to-use option.
Healthcare providers can quickly reconstitute and administer the medication,
which is especially vital for critical care scenarios. Lyophilized injectables
allow for precise dosing and accurate drug administration. In situations where
accurate dosing is critical, such as pediatric care or oncology treatments,
these formulations enhance patient safety. Lyophilized injectables are
versatile and suitable for use in various healthcare settings, including
hospitals, clinics, ambulatory care centers, and home healthcare. They can meet
the needs of patients in diverse situations.
The expansion of
healthcare infrastructure often leads to the development of biopharmaceutical
manufacturing hubs in certain regions. These hubs attract pharmaceutical
companies and research institutions, fostering innovation and drug development.
Lyophilized injectables are commonly used in biopharmaceutical manufacturing
due to their stability and suitability for biologic drugs. The establishment of
such manufacturing facilities contributes to the growing demand for lyophilized
injectables.
In recent times,
Lyophilized injectables have been widely used in recent times across various
medical specialties and therapeutic areas. Their use has expanded due to their
advantages in terms of stability, extended shelf life, and ease of
administration. Consequently, Lyophilized vaccines have played a crucial role
in global vaccination efforts, especially during the COVID-19 pandemic.
Vaccines like the Pfizer-BioNTech COVID-19 vaccine and the Moderna COVID-19
vaccine are examples of lyophilized formulations. These vaccines are
freeze-dried to maintain their stability and efficacy, allowing for easy
transportation, storage, and distribution, even in resource-constrained areas. Lyophilized
injectables are commonly used in oncology for the administration of
chemotherapy drugs, targeted therapies, and supportive care medications. These
formulations ensure accurate dosing and reduce the risk of dosage errors,
contributing to the safety and effectiveness of cancer treatments. Lyophilized
antibiotics and antimicrobials are essential in the treatment of severe
bacterial and fungal infections. These formulations offer prolonged shelf life,
which is crucial in hospital settings. They are often used in critical care
units and emergency departments to treat life-threatening infections. However,
the High Development and Manufacturing Costs may hinder market growth.
Moreover, challenges related to Regulatory Hurdles and Stringent Quality
Standards may pose obstacles to the Lyophilized Injectable market in the near
future.
The Global Lyophilized
Injectable Market is segmented into packaging, delivery, indication, end-user,
distribution channel, regional distribution, and company
Based on its
formulation, the Single-use vials are known for their exceptional ability to
maintain product integrity and stability. Lyophilized injectables are often
sensitive to moisture and temperature fluctuations, and single-use vials
provide an effective barrier against these environmental factors.
Pharmaceutical companies prioritize the preservation of product efficacy and
safety. Single-use vials help ensure that the lyophilized product remains
stable throughout its shelf life, reducing the risk of degradation and
maintaining consistent drug performance. Single-use vials are designed for
precise dosing and easy administration. They are typically available in various
sizes, allowing healthcare providers to select the appropriate volume for the
patient's needs. Moreover, they can be used for both reconstitution and
injection. Healthcare professionals value packaging that simplifies the dosing
process, especially for lyophilized injectables used in critical care settings.
Single-use vials offer convenience, accuracy, and flexibility in dosage
administration, enhancing their preference among clinicians.
Based on region,
North America segment is expected to grow during the forecast
period. North America, the United States and Canada, boasts
well-developed healthcare infrastructure with a high concentration of
hospitals, clinics, and specialized treatment centers. This infrastructure
supports the demand for lyophilized injectables, especially in hospitals and
specialty care settings. North America faces a significant burden of chronic
diseases, autoimmune disorders, and cancer. These conditions often require
lyophilized injectables for targeted and effective treatment, contributing to
the demand for these products. The region is home to numerous pharmaceutical
companies engaged in the research, development, and manufacturing of
lyophilized injectables. These companies cater to both domestic and global
markets, driving market growth. North America has stringent regulatory authorities,
such as the U.S. Food and Drug Administration (FDA) and Health Canada, which
enforce strict quality and safety standards for pharmaceutical products.
Compliance with these standards is crucial for market entry and contributes to
product quality.
The Asia-Pacific
market is poised to be the fastest-growing market, offering lucrative growth
opportunities for Lyophilized Injectable players during the forecast period.
Factors such as countries like India and China, has been experiencing
substantial growth in healthcare markets. This growth is driven by increasing
healthcare expenditures, rising income levels, and improving access to medical
services. As healthcare markets expand, there is a growing demand for a wide
range of pharmaceutical products, including lyophilized injectables. The
region's growing middle class is seeking better healthcare services, leading to
increased consumption of these products. Asia-Pacific is home to a vast and
diverse population, representing a significant patient pool for various medical
conditions. The region's sheer demographic size translates to high patient
numbers requiring treatment for chronic diseases, infectious diseases, and
oncology conditions. The prevalence of these diseases necessitates the use of
lyophilized injectables in various therapeutic areas. The sheer volume of
patients contributes to the growth of the market.
Major companies
operating in Global Lyophilized Injectable Market are:
- B. Braun Melsungen AG
- Baxter International Inc.
- BD & Co.
- Schott AG
- Aristopharma Ltd.
- Vetter Pharma GmbH
- Jubilant HollisterStier LLC
Download Free Sample Report
Customers can
also request for 10% free customization on this report
“The of Advancements
in Drug Delivery Technologies and increasing Demand for Biologics and Specialty
Drugs are key drivers of the Lyophilized Injectable market. In recent years, the
increasing prevalence of chronic conditions, such as diabetes, cancer, and
autoimmune diseases, has led to a higher demand for lyophilized injectables
used in the treatment of these diseases. Moreover, the growing consumer
emphasis on preventative healthcare products has enhanced production and
marketing efforts. To meet the demands of the market, manufacturers are
increasingly incorporating cutting-edge technologies with high production
efficiency. Rising consumer acceptance and continuous product innovation will
further ensure the growth of the Lyophilized Injectable and supplements market
in the coming years.,” said Mr. Karan Chechi, Research Director with TechSci
Research, a research-based management consulting firm.
“Lyophilized
Injectable Market – Global Industry Size, Share, Trends, Opportunity, &
Forecast 2018-2028 Segmented By Packaging (Single-Use Vials, Point-Of-Care
Reconstitution, Specialty Packaging), By Delivery (Prefilled Diluent Syringes,
Proprietary Reconstitution Devices, Single-Step Devices, Multi-Step Devices),
By Indication (Autoimmune Diseases, Infectious Diseases, Metabolic Conditions,
Others), By End-User (Autoimmune Diseases, Infectious Diseases, Metabolic
Conditions, Others), By Region & Competition”, has evaluated
the future growth potential of Global Lyophilized Injectable Market and
provides statistics & information on market size, structure and future
market growth. The report intends to provide cutting-edge market intelligence
and help decision makers take sound investment decisions. Besides, the report
also identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in Global Lyophilized Injectable Market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York 10017
Tel: +1-646-360-1656
Email: [email protected]
Website: www.techsciresearch.com